Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

201 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical effects and emerging issues of atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma from Japanese real-world practice.
Nakagawa M, Inoue M, Ogasawara S, Maruta S, Okubo T, Itokawa N, Iino Y, Obu M, Haga Y, Seki A, Kikuchi Y, Kogure T, Yumita S, Ishino T, Ogawa K, Fujiwara K, Iwanaga T, Fujita N, Sakuma T, Kojima R, Kanzaki H, Koroki K, Taida T, Kobayashi K, Kiyono S, Nakamura M, Kanogawa N, Kondo T, Nakagawa R, Nakamoto S, Muroyama R, Chiba T, Itobayashi E, Atsukawa M, Koma Y, Azemoto R, Ito K, Mizumoto H, Shinozaki M, Kato J, Kato N. Nakagawa M, et al. Among authors: atsukawa m. Cancer. 2023 Feb 15;129(4):590-599. doi: 10.1002/cncr.34559. Epub 2022 Nov 24. Cancer. 2023. PMID: 36426410 Free article.
Combination of fluvastatin with pegylated interferon/ribavirin therapy reduces viral relapse in chronic hepatitis C infected with HCV genotype 1b.
Atsukawa M, Tsubota A, Kondo C, Itokawa N, Narahara Y, Nakatsuka K, Hashimoto S, Fukuda T, Matsushita Y, Kidokoro H, Kobayashi T, Kanazawa H, Sakamoto C. Atsukawa M, et al. J Gastroenterol Hepatol. 2013 Jan;28(1):51-6. doi: 10.1111/j.1440-1746.2012.07267.x. J Gastroenterol Hepatol. 2013. PMID: 22989264 Clinical Trial.
Lead-in treatment with interferon-β/ribavirin may modify the early hepatitis C virus dynamics in pegylated interferon alpha-2b/ribavirin combination for chronic hepatitis C patients with the IL28B minor genotype.
Itokawa N, Atsukawa M, Tsubota A, Kondo C, Hashimoto S, Fukuda T, Matsushita Y, Kidokoro H, Kobayashi T, Narahara Y, Nakatsuka K, Kanazawa H, Iwakiri K, Sakamoto C. Itokawa N, et al. Among authors: atsukawa m. J Gastroenterol Hepatol. 2013 Mar;28(3):443-9. doi: 10.1111/jgh.12039. J Gastroenterol Hepatol. 2013. PMID: 23173698 Clinical Trial.
Efficacy of Alfacalcidol on PEG-IFN/ Ribavirin Combination Therapy for Elderly Patients With Chronic Hepatitis C: A Pilot Study.
Atsukawa M, Tsubota A, Shimada N, Kondo C, Itokawa N, Nakagawa A, Hashimoto S, Fukuda T, Matsushita Y, Kidokoro H, Narahara Y, Nakatsuka K, Iwakiri K, Kawamoto C, Sakamoto C. Atsukawa M, et al. Hepat Mon. 2013 Dec 23;13(12):e14872. doi: 10.5812/hepatmon.14872. eCollection 2013. Hepat Mon. 2013. PMID: 24403915 Free PMC article.
Serum 25-hydroxyvitamin D3 levels affect treatment outcome in pegylated interferon/ribavirin combination therapy for compensated cirrhotic patients with hepatitis C virus genotype 1b and high viral load.
Atsukawa M, Tsubota A, Shimada N, Kondo C, Itokawa N, Nakagawa A, Hashimoto S, Fukuda T, Matsushita Y, Narahara Y, Iwakiri K, Nakatsuka K, Kawamoto C, Sakamoto C. Atsukawa M, et al. Hepatol Res. 2014 Dec;44(13):1277-85. doi: 10.1111/hepr.12298. Epub 2014 Feb 26. Hepatol Res. 2014. PMID: 24417888
Effect of fluvastatin on 24-week telaprevir-based combination therapy for hepatitis C virus genotype 1b-infected chronic hepatitis C.
Atsukawa M, Tsubota A, Shimada N, Kondo C, Itokawa N, Nakagawa A, Fukuda T, Matsushita Y, Narahara Y, Osada Y, Yamaguchi H, Nakatsuka K, Iwakiri K, Kawamoto C, Sakamoto C. Atsukawa M, et al. Eur J Gastroenterol Hepatol. 2014 Jul;26(7):781-7. doi: 10.1097/MEG.0000000000000105. Eur J Gastroenterol Hepatol. 2014. PMID: 24732752 Clinical Trial.
Vitamin D-related gene polymorphisms do not influence the outcome and serum vitamin D level in pegylated interferon/ribavirin therapy combined with protease inhibitor for patients with genotype 1b chronic hepatitis C.
Arai T, Atsukawa M, Tsubota A, Kondo C, Shimada N, Abe H, Itokawa N, Nakagawa A, Okubo T, Aizawa Y, Iwakiri K. Arai T, et al. Among authors: atsukawa m. J Med Virol. 2015 Nov;87(11):1904-12. doi: 10.1002/jmv.24244. Epub 2015 May 11. J Med Virol. 2015. PMID: 25964133
201 results